Clinical trials: Resectable Small Cell Lung Cancer
NSCLC, Neoadjuvant Therapy
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
This is a randomized, open-label, multicenter phase II study. The trial plans to enroll 164 subjects with resectable stage IIA-IIIB (N2) NSCLC.
- Conditions
- NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112
- Trial name
- NEOINSPIRE (NCT07086326)
- Testing
- Ivonescimab+Chemo, Penpulimab+Chemo
- Where
- 5 sites in China
- Volunteers
- 164 people
- Sponsor
- Yang Fan, MD
Non Small Cell Lung Cancer, Stereotactic Body Radiotherapy
Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.
This is an open-label, randomized, controlled, multicenter phase III clinical trial designed to evaluate the efficacy and safety of spatially fractionated stereotactic body radiotherapy (SF-SBRT) combined with toripalimab and…
- Conditions
- Non Small Cell Lung Cancer, Stereotactic Body Radiotherapy, Neoadjuvant Chemoimmunotherapy, Surgery
- Trial name
- NCT07608159
- Testing
- Stereotactic body radiotherapy (SBRT), neoadjuvant immunotherapy, Neoadjuvant Chemotherapy
- Volunteers
- 201 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-small Cell Lung Cancer
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
This trial is a registrational Phase II/III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib in resectable EGFR-mutant non-small cell lung cancer.
- Trial name
- NCT07642024
- Testing
- BL-B01D1, Osimertinib, Carboplatin
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Lung Cancer
Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer
The goal of this clinical research study is to learn about the safety and effectiveness of OSI-774 when combined with standard chemotherapy (carboplatin and paclitaxel) before surgery in the treatment of non-small cell lung…
- Trial name
- NCT00063258
- Testing
- Tarceva (OSI-774), Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
NSCLC Stage II, NSCLC, Stage IIIA
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients
The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung…
- Conditions
- NSCLC Stage II, NSCLC, Stage IIIA, NSCLC, Stage I
- Trial name
- NEOpredict (NCT04205552)
- Testing
- Nivolumab 10 MG/ML Intravenous Solution, Relatlimab 10 MG/ML Intravenous Solution
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 90 people
- Sponsor
- University Hospital, Essen
Efficacy and Safety
Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.
JS001 (Toripalimab) is a recombinant humanized anti-PD-1 monoclonal antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.
- Trial name
- NAJSCR (NCT03623776)
- Testing
- JS001, Pemetrexed, Carboplatin
- Where
- China
- Sponsor
- Sun Yat-sen University
Resectable Non-small Cell Lung Cancer
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
This study is researching an experimental drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and platinum-doublet chemotherapy, individually called a "study drug" or collectively called…
- Trial name
- NCT06161441
- Testing
- Fianlimab, Cemiplimab, Pemetrexed
- Where
- 123 sites in United States, Australia and 10 more
- Volunteers
- 195 people
- Sponsor
- Regeneron Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer
This is a Phase I Trial evaluating the safety of the dietary supplement honokiol for lung cancer chemoprevention. Female or male patients aged 18 years, or older, with early stage lung cancer who have been scheduled for curative…
- Trial name
- NCT06566443
- Testing
- Honokiol
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Methodist Hospital Research Institute
Lung Cancer
Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC
This study is a prospective, single-arm, single-center Phase II trial, aiming to investigate efficacy and safety of neoadjuvant chemotherapy sequentially combined with sintilimab in resectable EGFR-mutant stage II-IIIB…
- Trial name
- Peri-E (NCT06688656)
- Testing
- Pemetrexed 500 mg/m2, carboplatin, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Chest Hospital
Non-small Cell Lung Cancer Stage III, Borderline Resectable Carcinoma
Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC
A Phase II, interventional study of neoadjuvant durvalumab (MEDI 4736) and platinum-based Chemotherapy, followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants…
- Trial name
- ACCESS (NCT06998719)
- Testing
- Durvalumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Bi Nan
EGF-R Positive Non-Small Cell Lung Cancer
The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC
This study aimed to assess the value of dynamic ctDNA monitoring in guiding the development of personalized neoadjuvant treatment strategies for EGFR-mutated NSCLC patients.
- Trial name
- NCT06287593
- Testing
- ctDNA monitoring
- Volunteers
- 300 people
- Sponsor
- Zhejiang University
Non-small Cell Lung Cancer, NSCLC
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
Resectable, locally advanced NSCLC with involvement of mediastinal lymph nodes (N2) is associated with a high risk of (systemic) recurrence despite neo-adjuvant chemotherapy.
- Trial name
- NCT04245514
- Testing
- Durvalumab, Radiotherapy
- Where
- 13 sites in Germany, Switzerland
- Volunteers
- 90 people
- Sponsor
- Swiss Cancer Institute
Potentially Resectable ALK Positive Non-Small Cell Lung Cancer
Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial
Fusion of anaplastic lymphoma kinase (ALK) is an important driving gene for NSCLC, with an incidence rate of 3-7%. In patients with advanced ALK mutation NSCLC, first-line use of ALK inhibitors significantly improves progression…
- Trial name
- NCT06282536
- Testing
- Iruplinalkib, surgery
- Volunteers
- 20 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non Small Cell Lung Cancer
Evaluation of Preoperative Endobronchial Ultrasound (EBUS) in Non Small Cell Lung Cancer (NSCLC)
This study aims to assess both the role and cost-effectiveness of EBUS in preoperative Non small cell lung cancer staging. This controlled multicentric study will be conducted in 22 centers in France.
- Trial name
- EVIEPEB (NCT00960271)
- Testing
- EBUS
- Where
- France
- Volunteers
- 363 people
- Sponsor
- University Hospital, Rouen
Non-Small Cell Carcinoma of Lung, Gut Microbiomes
Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC
Locally advanced lung cancer (LALC) has poor prognosis despite multimodal therapies. Neoadjuvant chemoimmunotherapy is now standard for resectable stage II-IIIB NSCLC, but patient responses vary.
- Conditions
- Non-Small Cell Carcinoma of Lung, Gut Microbiomes, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT07752589
- Testing
- Neoadjuvant chemoimmunotherapy
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guangdong Provincial People's Hospital
Lung Cancer Stage II, PD-1 Antibody
A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC
This study is a randomized, controlled, open-label, prospective, single-center phase II clinical study. Target population is patients with stage II and IIIA resectable non-small cell lung cancer who had not received systemic…
- Conditions
- Lung Cancer Stage II, PD-1 Antibody, Non-small Cell Lung Cancer
- Trial name
- NCT04108013
- Testing
- SHR-1210, Carboplatin and Paclitaxel-albumin
- Volunteers
- 38 people
- Sponsor
- Xuanwu Hospital, Beijing
Lung Diseases, Carcinoma, Non-Small-Cell Lung
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
Open-label, phase III, randomized, stratified (PDL1- vs PDL1+), 3 arms, multicenter clinical trial. 129 resected patients (43 per arm) with stage from IB to IIIA and IIIB (N2) non-small cell lung cancer that do not achieve…
- Conditions
- Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma
- Trial name
- ARIAN (NCT06431633)
- Testing
- Zimberelimab, Sacituzumab govitecan, Cisplatin
- Where
- 32 sites in Spain
- Volunteers
- 129 people
- Sponsor
- Fundación GECP
Resectable Lung Non-Small Cell Carcinoma
Impact of Surgical Approach on Adaptation of Posture-respiratory Coupling
This study aims to identify physiopathologic mechanisms related to surgical approaches during lobectomies for non-small cell lung cancer which can explain the better quality of life and the decrease of of post-operative…
- Trial name
- VaPosVent (NCT06276530)
- Testing
- EOS imaging for musculoskeletal disorder, Movement analysis by an optoelectronic camera., Stabilometric measurement by strength platform
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8
Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
This phase II trial tests how well a fixed dose combination (FDC) of cemiplimab and fianlimab before surgery (neoadjuvant) works in treating patients with stage IB-IIIB non-small cell lung cancer (NSCLC).
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- N-PLANC (NCT06918132)
- Testing
- Biospecimen Collection, Cemiplimab, Fianlimab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Non-Small-Cell Lung Cancer
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
This trial is designed to evaluate the efficacy, safety and immunogenicity of neoadjuvant treatment with monoclonal antibody SHR-1316 or placebo in combination with platinum doublet chemotherapy in participants with resectable…
- Trial name
- NCT04316364
- Testing
- SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin, SHR-1316、Chemotherapeutic
- Where
- 7 sites in China
- Volunteers
- 537 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.